JNJ · News · 20261021N

Product Growth and Competition

JOHNSON & JOHNSON · 2026-10-21 · Importance 24 · Surprise 24

Johnson & Johnson’s prescription-drug portfolio is described as strong enough to support overall performance, particularly in cancer and immune-disease treatments. The company’s medical-device businesses serve heart, eye, and orthopaedic surgery markets, but the device side is characterized as needing to catch up. New-drug growth is expected to offset declining demand for STELARA. The competitive environment includes Bristol Myers Squibb and other developers pursuing earlier-line multiple-myeloma treatments.